SCHEMBL11907398

SCHEMBL11907398

Nc1ccc(-c2cncs2)nc1C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K3 P46734 2/20 0.42
MYC P01106 1/20 0.38
CHEK1 O14757 1/20 0.36
CHEK2 O96017 1/20 0.36
KDM4E B2RXH2 5/20 0.36
ALDH1A1 P00352 5/20 0.36
PIM1 P11309 4/20 0.35
PIM3 Q86V86 4/20 0.35
PIM2 Q9P1W9 4/20 0.35
MEN1 O00255 3/20 0.34
KMT2A Q03164 3/20 0.34
RAB9A P51151 2/20 0.34
IMPDH2 P12268 1/20 0.34
NPC1 O15118 1/20 0.34
POLB P06746 1/20 0.34
CD38 P28907 1/20 0.34
TDP1 Q9NUW8 2/20 0.33
MAPT P10636 2/20 0.33
HPGD P15428 1/20 0.33
MCL1 Q07820 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11909835 0.78 KDM4E (0.57) MAP2K3KDM4EALDH1A1MEN1KMT2A
SCHEMBL11907875 0.75 MAP2K3 (0.51) MAP2K3KDM4EALDH1A1PIM1PIM3
SCHEMBL11906831 0.74 MEN1 (0.46) MAP2K3KDM4EALDH1A1MEN1KMT2A
SCHEMBL11906886 0.74 KDM4E (0.49) MAP2K3KDM4EALDH1A1MEN1KMT2A
SCHEMBL11908992 0.74 MAP2K3 (0.40) MAP2K3KDM4EALDH1A1TDP1KDM6B
SCHEMBL11908776 0.73 MAP2K3 (0.53) MAP2K3KDM4EALDH1A1PIM1PIM3
SCHEMBL11907722 0.72 MAP2K3 (0.51) MAP2K3KDM4EALDH1A1TDP1MAPT
SCHEMBL25136438 0.72 ECE1 (0.51) MYCKDM4EPIM1TDP1
SCHEMBL11906982 0.72 MAP2K3 (0.44) MAP2K3KDM4EALDH1A1PIM1PIM3
SCHEMBL13822164 0.72 ASIC3 (0.47) MYCKDM4EALDH1A1PIM1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2014-09-04 US disclosed
US-8822497-B2 PIM kinase inhibitors and methods of their use NOVARTIS AG (CH) 2014-09-02 US disclosed
EP-2132177-B1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2013-07-17 EP disclosed
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE NOVARTIS AG (CH) 2012-08-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140249135-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MAP2K3 197/4885MYC 53/4885CHEK1 70/4885
US-20120208815-A1 PIM KINASE INHIBITORS AND METHODS OF THEIR USE PIM1, PIM2, PIM3 MAP2K3 197/4885MYC 53/4885CHEK1 70/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.